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JAK2V617F is the most common oncogenic lesion in
patients with myeloproliferative neoplasms (MPNs).
Despite the ability of JAK2V617F to instigate DNA
damage in vitro, MPNs are nevertheless character-
ized by genomic stability. In this study, we address
this paradox by identifying the DNA helicase
RECQL5 as a suppressor of genomic instability in
MPNs. We report increased RECQL5 expression in
JAK2V617F-expressing cells and demonstrate that
RECQL5 is required to counteract JAK2V617F-
induced replication stress. Moreover, RECQL5
depletion sensitizes JAK2V617F mutant cells to hy-
droxyurea (HU), a pharmacological inducer of repli-
cation stress and the most common treatment for
MPNs. Using single-fiber chromosome combing,
we show that RECQL5 depletion in JAK2V617F
mutant cells impairs replication dynamics following
HU treatment, resulting in increased double-
stranded breaks and apoptosis. Cumulatively, these
findings identify RECQL5 as a critical regulator of
genome stability in MPNs and demonstrate that
replication stress-associated cytotoxicity can be
amplified specifically in JAK2V617F mutant cells
through RECQL5-targeted synthetic lethality.INTRODUCTION
The propensity of cancer cells to undergo clonal evolution is
enabled by a heightened state of genomic instability wherein
cancer cells are continuously accumulating and repairing DNA
damage. This increase in genomic flux allows cancer cells to
accumulate somatic mutations that can drive disease progres-Cell Repsion. However, heightened genomic instability can also activate
DNA damage-associated checkpoints, which can lead to
apoptosis or cellular senescence. Cancer cells continuously
tread a fine balance between cell death and survival in response
to DNA damage (Negrini et al., 2010).
Chronic myeloproliferative neoplasms (MPNs) encompass a
spectrum of clonal hematological disorders with an inherent ten-
dency to transform into a more aggressive disease in the form of
acute myeloid leukemia (AML). MPNs provide a window into
cancer early during its ontogeny and give insights into the pro-
cesses that regulate genome stability during malignant clonal
evolution. The most common recurrent lesion in MPN patients
is an activating V617F mutation in the JAK2 non-receptor tyro-
sine kinase (JAK2V617F) that causes hyperactive JAK-STAT
signaling and confers a capacity for cytokine-independent
growth (Baxter et al., 2005; James et al., 2005; Kralovics et al.,
2005; Levine et al., 2005). Recently, a growing body of work
has suggested that JAK2V617F is associated with increased
DNA damage: (1) increased numbers of gH2Ax-marked dou-
ble-strand breaks (DSBs) have been detected in Ba/F3 pro-B
cells overexpressing JAK2V617F (Marty et al., 2013) and in line-
age-negative, Sca1-positive, c-Kit-positive (LSK) cells (enriched
for hematopoietic stem cell [HSC] activity) from 6-month-old
JAK2V617F-heterozygous knockin mice (Li et al., 2010);
(2) JAK2V617F expression is associated with increased levels
of DNA-damaging reactive oxygen species (Marty et al., 2013);
(3) RAD51-positive foci indicative of increased DSB repair have
been observed in CD34+ hematopoietic cells obtained from
JAK2V617F-positive MPN patients (Plo et al., 2008); and (4)
JAK2V617F expression in both human diploid fibroblasts and
primary erythroblasts from MPN patients leads to higher rates
of stalled replication forks, with improper processing of stalled
replication intermediates representing a potential source of
DSBs (Chen et al., 2014).
Given the genome-destabilizing functionalities of JAK2V617F
and the inherent tendency for leukemic transformation in pa-
tients with MPN, a reasonable supposition is that oncogenicorts 13, 2345–2352, December 22, 2015 ª2015 The Authors 2345
Figure 1. JAK2V617F Increases the Expres-
sion of RECQL5
(A) Gene expression profiles depicting the expres-
sion of 25 DNA helicases in 40MPN patients (20 ET
patients, 16 PV patients, and 4 MF patients).
(B) qPCR validation of RECQL5 and RECQL1
expression in ET (blue) and PV (red) patients.
(C) RECQL5 expression in SET-2 and HEL cells
following treatment with 0–8 mM of the JAK2 in-
hibitor INCB18424.
(D and E) Expression of Recq family members in
WT-B8 and VF-B8 cells by qPCR (D) and western
immunoblot (E). *p < 0.01.
(F) Recql5 expression in WT-B8 and VF-B8 cells
following knockdown of Jak2 (sh-Jak2), the p85
subunit of PI3K (sh-Pi3k), Stat1 (sh-Stat1), or Stat5
(sh-Stat5).
(G) RECQL5 expression in HEL cells following
knockdown of JAK2 (sh-JAK2), STAT5 (sh-STAT5),
or STAT1 (sh-STAT1).
(H) RECQL5 expression in HEL cells following
treatment for 16 hr with INCB018424 (1 mM), the
PI3K inhibitor PI103 (1 mM), or the ERK1/2 inhibitor
U0126 (5 mM).
See also Figure S1.JAK2 signaling imposes a mutator phenotype on MPN cells,
accelerating the accumulation of mutations and promoting
clonal evolution and disease progression. However, longitudinal
studies of MPN patients indicate that JAK2V617F-positive poly-
cythemia vera (PV) and essential thrombocythemia (ET) patients
(i.e., chronic-phase MPN) typically remain clinically and cytoge-
netically stable over decades (Tefferi et al., 2014). A recent copy-
number analysis of the genome of chronic-phase MPN patients
has shown that cytogenetic abnormalities are rare (Klampfl et al.,
2011), and an analysis of the mutational landscape of PV and ET
patients revealed that each MPN patient harbors a modest num-
ber of mutations per exome (approximately 6.5) (Nangalia et al.,
2013).
To reconcile the apparent paradox of JAK2V617F-induced
DNAdamagewith the clinical andcytogenetic stability character-
istic of chronic-phaseMPN,we hypothesized that JAK2V617F, in
addition to instigating a state of increased DNA damage, could
also, in parallel, activate protective pathways that counteract
and prevent DNA damage-induced apoptosis. In this report, we2346 Cell Reports 13, 2345–2352, December 22, 2015 ª2015 The Authorsidentify increased expression of the DNA
repair helicase RECQL5 in JAK2V617F-
expressing cells and characterize its role
in constraining JAK2V617F-induced repli-
cation stress and maintaining genomic
integrity in MPNs.
RESULTS
Activated JAK2 Signaling Regulates
Expression of the RECQL5 Helicase
in MPN Cells
We analyzed the gene expression profiles
of autologous normal and JAK2V617F-heterozygous burst-forming unit erythroid (BFU-E) colonies
from 40 MPN patients (Chen et al., 2010). To explore the hypoth-
esis that JAK2V617F may activate genes that counteract DNA
damage, we evaluated the expression of DNA helicases in
JAK2 mutant and autologous normal cells in this dataset. Of 25
DNA helicases expressed, RECQL5 was the sole DNA helicase
enzyme whose expression was elevated significantly in
mutant-JAK2 BFU-Es relative to autologous BFU-Es in ET, PV,
and myelofibrosis (MF) patients after multiple hypothesis testing
(q < 0.05) (Figure 1A). Real-time qPCR analysis of 10 MPN pa-
tients (five PV patients and five ET patients) demonstrated
increased expression of RECQL5 (but not the related RECQ fam-
ily member RECQL1) in mutant JAK2 colonies relative to autolo-
gous wild-type colonies in both PV and ET patients (Figure 1B).
We next assessed RECQL5 levels following JAK2 inhibition in
two independent cell lines that harbor the JAK2V617F mutation:
HEL and SET-2 cells. We found that treatment of the erythroleu-
kemic cell line HEL and themegakaryoblastic cell line SET-2 with
the JAK2 inhibitor INCB018424 reduced RECQL5 expression
concomitant with decreasedSTAT5 phosphorylation (Figure 1C).
In aggregate, these data indicate that RECQL5 expression is
regulated by activated JAK2 signaling in human disease-relevant
contexts.
Physiological Levels of Jak2V617F Lead to Increased
Recql5 Expression
To investigate the role of Recql5 under conditions that more
closely recapitulate chronic-phase MPN in patients, we gener-
ated disease-relevant cell lines from Jak2V617F knockin mice
thatwedevelopedpreviously andcharacterizedextensively (Mul-
lally et al., 2010, 2013). This mouse model closely recapitulates
the features of human MPN, and Jak2V617F expression is phys-
iological in the model, being driven from the endogenous Jak2
promoter. To generate cell lines, we engineered bone marrow
progenitors from littermate wild-type or Jak2V617F knockin
mice to express a b-estradiol-regulated Hoxb8 homeodomain-
containing protein. Following 3 weeks of serial passaging and
antibiotic selection, immortalized myeloid progenitor cells were
generated from both wild-type mice (WT-B8) and Jak2V617F
knockin mice (VF-B8) (Wang et al., 2006). Both the WT-B8 and
VF-B8 lines resemble cells at a granulocyte-macrophage progen-
itor (GMP) stage of myeloid maturation by cell surface immuno-
phenotype analysis (Figure S1A). Immunoblotting showed
equivalent levels of Jak2 expression in both cell lines but
increased levels of phosphorylated Stat5 in VF-B8 cells relative
to WT-B8 cells (Figure S1B). Additionally, VF-B8 cells exhibited
an increased proliferative capacity and survival under reduced
serum conditions (Figures S1C–S1D), indicating that VF-B8 cells
recapitulate this key pathognomonic feature of MPN biology.
We next determined whether the expression of Recql5 was
modulated by mutant Jak2 in these Hoxb8-immortalized cell
lines. In accordancewith theprimary humandata, VF-B8cells ex-
hibited elevated expression of Recql5 relative to WT-B8 cells by
qPCR analysis (Figure 1D) and western immunoblotting (Fig-
ure 1E). No significant differential expression of other Recq family
members (Recql1, Recql4, Blm, and Wrn) was observed. These
data demonstrate that mutant JAK2 increases expression of
theDNA repair helicaseRECQL5 in both human andmurine cells.
RECQL5 Is a Target of JAK2-PI3K Signaling
To determine which signaling pathways were necessary for the
regulation of Recql5 by Jak2V617F, we used small hairpin
RNAs (shRNAs) to knock down Jak2 and downstream effector
molecules of Jak2 in VF-B8 cells. Expression of shRNAs target-
ing Jak2 led to diminution of Recql5 levels relative to cells
transduced with an empty vector control (Figure 1F), which is
consistent with the finding that Recql5 is a downstream target
of Jak2 signaling. Next, we assessed Recql5 levels in VF-B8 cells
following transduction of shRNAs targeting Stat1, Stat5, or the
p85 subunit of phosphatidylinositol 3-kinase (PI3K). The levels
of Recql5 in VF-B8 cells were reduced following knockdown of
PI3K but not Stat1 or Stat5 (Figure 1F). Similarly, RECQL5 levels
were also attenuated following knockdown of JAK2 in HEL cells
but were not attenuated following knockdown of STAT5 or
STAT1 (Figure 1G), and treatment of HEL cells with the PI3K in-
hibitor PI103 (but not the ERK1/2 inhibitor U0126) led to attenu-
ated levels of RECQL5, accompanied by decreased AKTCell Repphosphorylation (Figure 1H). Taken together, these data indicate
that RECQL5 expression is increased upon JAK2 activation in a
PI3K-dependent manner.
Recql5 Depletion Sensitizes Jak2V617F-Expressing
Cells to Replication Stress
We next sought to clarify the function of RECQL5 upregulation in
JAK2V617F-expressing cells. Previously, we had demonstrated
that overexpression of JAK2V617F in human diploid fibroblasts
resulted in increased replication fork stalling and replication
stress (Chen et al., 2014). Because RECQL5 has been linked
functionally to regulating stalled replication forks in normal cells,
we hypothesized that the upregulation of RECQL5 may function
to mitigate the deleterious consequences of replication stress in
JAK2 mutant cells.
To test this, we knocked down Recql5 in VF-B8 cells using
three independent shRNAs (Figure S2A). Densitometric analysis
revealed a knockdown efficiency of 61%–95% for the three hair-
pins. Under normal growth conditions, Recql5 knockdown in VF-
B8 cells did not affect the proliferation rate (Figure S2B) or
apoptosis (Figure S2C) relative to either equivalently modified
WT-B8 cells or VF-B8 cells expressing empty vector alone (VA)
controls. To simulate replication stress, we subjected WT-B8
and VF-B8 cells to low-serum conditions to deprive cells of de-
oxynucleotide triphosphate (dNTP) (Bester et al., 2011). We
observed that VA-expressing VF-B8 cells exhibited greater
viability relative to WT-B8 cells under low-serum conditions (Fig-
ure 2A, left), which is in accordance with our previous data on
non-genetically perturbed cells. In contrast, Recql5-depleted
VF-B8 cells exhibited decreased viability relative to equivalently
modified WT-B8 cells (Figure 2A, right). Hypersensitivity of
Recql5-depleted VF-B8 cells to low-serum conditions was abro-
gated completely upon repletion of deoxynucleotide (dNTPs)
into the culture medium (Figure 2B). The results shown represent
the average of three independent Recql5-targeting shRNAs and
are consistent with data obtained for each individual hairpin (Fig-
ure S2D). Collectively, these data demonstrate that Recql5 pro-
tects VF-B8 cells from endogenous replication stress instigated
by low dNTP levels.
We next tested whether Recql5 depletion would also sensitize
VF-B8 cells to exogenous instigators of replication stress, such
as pharmacological agents. We tested hydroxyurea (HU) and
camptothecin (CPT), which impair DNA replication by limiting
production of dNTPs and inhibiting topoisomerase I activity,
respectively. Strikingly, contemporaneous knockdown of Recql5
and exposure to either HU or CPT led to significantly decreased
viability of VF-B8 cells compared with like-treated WT-B8 cells
after 24 hr of drug treatment (Figures 2C, 2D, and 2G; Fig-
ure S2D). Decreased cell viability was noted as early as 12 hr
post-drug treatment (Figures S2E and S2F). In contrast,
Recql5-depleted VF-B8 cells were not hypersensitive to the dou-
ble-stranded breaking agents doxorubicin (DOX) and etoposide
(ETP) (Figures 2E and 2F; Figure S2D). Concordant with these
data, shRNA depletion of human RECQL5 also enhanced cyto-
toxicity in HEL and SET2 cells, but only to pharmacological insti-
gators of replication stress (HU, CPT, aphidicolin, and irinotecan)
and not to pro-oxidants or DSB-generating drugs (Figures S2G
and S2H).orts 13, 2345–2352, December 22, 2015 ª2015 The Authors 2347
Figure 2. Recql5 Depletion Sensitizes
Jak2V617F-Expressing Cells to Replication
Stress
(A–F) Viability of WT-B8 (black) and VF-B8 (red) cells
transduced with VA or Recql5-targeting shRNAs
following serum deprivation (SD) in 0.5% fetal calf
serum (FCS) (A), SD with 100 mM dNTPs (SD + dNTPs)
(B), HU (0–250 mM) (C), CPT (0–10 nM) (D), DOX
(0–25 mM) (E), or ETP (0–10 nM) (F). For VA-transduced
cultures, each point represents the mean of three in-
dependent cultures. For Recql5-knockdown cultures,
each point represents the mean of three separate
Recql5-targeting shRNAs.
(G) Quantitation of annexin V positivity in cells treated
with 100 mM HU or 4 nM CPT.
(H–J) VF-B8 cells were transduced with Recql5-tar-
geting shRNA simultaneously with either a wild-type
Recql5 cDNA (RQ5wt), shRNA-resistant Recql5 cDNA
(RQ5res), or RQ5res cDNA harboring a K58Rmutation
(RQ5res-K58R). Immunoblotting for Recql5 protein
levels was performed (H), and cell viability was as-
sessed (I and J).
Testing for statistical significance was performed us-
ing Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001).
See also Figure S2.Replication stressors such as HU and CPT can also induce
DSBs at sufficiently high doses. We therefore validated whether
the HU and CPT doses associated with preferential cytotoxicity
of Recql5-depleted VF-B8 cells were causing increased replica-
tion stress or excessive formation of DSBs. To differentiate be-
tween these two phenomena, we treated parental WT-B8 and
VF-B8 cells with HU (6 mM) and CPT (4 nM) and performed immu-
nocytochemical staining for foci containing theRPAprotein (which
marks stalled replication forks) or 53BP1 (which localizes toDSBs)
(Figures S3A and S3B). At these HU and CPT dosages, we
observed a marked increase in foci containing RPA (Figure S3C),
with only a marginal increase in numbers of 53BP1-positive foci
(Figure S3D). In contrast, etoposide (4 nM) generated both RPA-
positive and 53BP1-positive foci (Figures S3C andS3D). In aggre-
gate, these findings verify that the dosage of HU and CPT used to
enhance the cytotoxicity of Recql5-depleted VF-B8 cells causes
enhanced replication stress with only a slight elevation of DSBs.2348 Cell Reports 13, 2345–2352, December 22, 2015 ª2015 The AuthorsGiven the potential off-target effects of
shRNAs that may potentially influence the
observed phenotypes, we next confirmed
the specificity of the Recql5 shRNAs.We de-
signed a Recql5 cDNA), RQ5(res), that was
mutated at every third nucleotide to disrupt
each of the shRNA-binding sites while retain-
ing the correct amino acid encoded at each
triplet codon. Expression of a wild-type
Recql5 (RQ5(WT)) in VF-B8 cells together
with a Recql5-targeting shRNA did not
rescue Recql5 expression (Figure 2H) and
failed to abrogate the increased sensitivity
of Recql5-depleted VF-B8 cells to HU (Fig-
ure 2I). In contrast, expression of RQ5(res)
resulted in high levels of Recql5 expressionthat were maintained despite expression of a Recql5 shRNA
(Figure 2H) and successfully abrogated the hypersensitivity to
HU of the VF-B8 cells co-expressing the Recql5 shRNA (Fig-
ure 2I). Moreover, a RQ5(res) cDNA harboring a K58R mutation
within the helicase domain is incapable of abrogating HU hyper-
sensitivity, revealing the essentiality of Recql5 helicase activity in
protecting against replication stress (Figure 2J). Together, these
data demonstrate that the effects of the shRNAs were on target
and that Recql5 depletion was the critical factor for conferring
increased sensitivity of VF-B8 cells to replication stress.
Recql5 Depletion Increases the Severity of Replication
Fork Stalling in Jak2V617F-Expressing Cells Exposed to
Exogenous Replication Stress
To understand the molecular mechanisms by which Recql5
depletion in VF-B8 cells leads to increased cytotoxicity by
exogenous replication stressors (such as HU), we performed
Figure 3. Recql5 Protects against the
Collapse of Stalled Replication Forks in
Jak2V617F-Expressing Cells Exposed to
Replication Stress
(A) Schematic of the time course for chromosome
combing experiments (top). Shown are represen-
tative replication structures of a single combed
DNA molecule labeled with IdU (red) and CldU
(green) (bottom).
(B) Fork rate in WT-B8 and VF-B8 cells transduced
with empty vector alone (VA) or with two different
Recql5-targeting shRNAs (sh1 and sh2). The re-
sults represent the mean ± SD for at least 50 fibers.
(C) Quantification of HU-induced effects on fork
dynamics. Relative fork progress is depicted as the
normalized ratio of the second (HU-treated) label-
ing step relative to the first (HU-free) labeling step.
(D–F) Schematic of the timeline for fork restart ex-
periments (D). Also shown are quantification of
BrdU-positive cells (E) and representative flow cy-
tometric plots of BrdU staining (F).
(G and H) Quantification of gH2Ax-marked double-
stranded breaks as assessed by immunofluores-
cence detection (G) and western immunoblot (H).
(D–H) Testing for statistical significance was per-
formed using Student’s t test (*p < 0.05; **p < 0.01;
n.s., not significant).
See also Figure S2.chromosome combing, which allows the direct visualization and
analysis of replication tracts on individual, bromodeoxyuridine
(BrdU)-labeled DNA fibers. We subjected WT-B8 or VF-B8 cells
transduced with Recql5-targeting shRNAs or VA controls to this
procedure. All cultures underwent a first labeling step with the
BrdU analog iododeoxyuridine (IdU) under normal growth condi-
tions, followed by a second labeling step with another BrdU
analog, chlorodeoyuridine (CldU), in culture medium supple-
mented with HU (Figure 3A). In this way, the extent of fork pro-
gression can be measured both in the absence and presence
of HU to determine any differential effects of HU on the cultures.
We focused our initial analysis on fibers generated solely from
the first labeling step to ascertain whether Recql5 depletion in
the absence of HU altered DNA replication kinetics. For this anal-
ysis, we measured the length of these fibers and calculated the
average fork rate because decreased fork processivity is a
robust indicator of fork stalling. In control cells, we observed a
significant decrease in the mean replication rate in VF-B8 cells
compared with WT-B8 cells (1.47 ± 0.18 kb/min [n = 88] in
VF-B8 cells versus 1.97 ± 0.21 kb/min [n = 94] in WT-B8 cells
[p < 0.01]) (Figure 3B), consistent with reports published
previously indicating a replication processivity impairment in
JAK2V617F-expressing cells (Chen et al., 2014). However, the
mean replication rate was not altered significantly by Recql5
knockdown in either WT-B8 or VF-B8 cells (WT-B8+sh1,
1.88 ± 0.44 kb/min [n = 80]; WT-B8+sh2, 1.91 ± 0.28 kb/min
[n = 55]; VF-B8+sh1, 1.33 ± 0.31 kb/min [n = 101]; VF-B8+sh2,
1.32 ± 0.39 kb/min [n = 50]). Critically, no difference was
observed in fork rate between VF-B8 cells depleted for Recql5
relative to those transduced with an empty vector (Figure 3B).
These data indicate that physiological levels of Jak2V617F
expression in myeloid cells gives rise to a replication stressCell Repphenotype, as evidenced by decreased fork processivity, but
that Recql5 depletion alone has no additional affect.
We next explored the possibility that depletion of Recql5 in
WT-B8 and VF-B8 cells could lead to altered replication dy-
namics in the presence of HU. Because replication fork progress
in VF-B8 cells is impaired globally relative to WT-B8 cells, to
facilitate comparison, the extent of fork progress during the first
(HU-free) labeling stepwas normalized and arbitrarily designated
at 1, and the second (HU-treated) labeling step was depicted
relative to the normalized first label. Using this analysis, we
observed that the presence of HU impaired fork progression in
all cultures tested (Figure 3C). However, the impairment in fork
progression caused by exposure to HU was significantly greater
in Recql5-depleted VF-B8 cells relative to control VF-B8 cells
and Recql5-depleted WT-B8 cells (Figure 3C). This indicates
that Recql5 depletion differentially impairs replication fork pro-
gression in VF-B8 cells following HU exposure compared with
WT-B8 cells.
The exacerbation in impairment of fork progression may be
due to an increased frequency of fork collapse. To test for this,
we measured the restart efficiency of a stalled replication fork,
a process that is highly impaired following fork collapse. VF-B8
cells transduced with a control shRNA or shRNAs targeting
Recql5 were initially exposed to HU for 60 min, followed by
removal of HU and addition of BrdU (Figure 3D). Flow cytometric
detection of BrdU-positive cells reflected cells that had effi-
ciently restarted stalled forks. We observed significantly fewer
BrdU-positive cells in HU-treated Recql5-depleted VF-B8 cells
compared with cells expressing control hairpins (Figures 3E
and 3F). Consistent with a role for Recql5 in protecting VF-B8
cells against HU-induced fork collapse, we noted that,
following HU exposure, Recql5-depleted VF-B8 cells exhibitedorts 13, 2345–2352, December 22, 2015 ª2015 The Authors 2349
Figure 4. RECQL5 Depletion Sensitizes
JAK2V617F-Positive Cells from MPN Pa-
tients to Replication Stressors
(A) Workflow for determining the effect of RECQL5
knockdown on the HU sensitivity of primary MPN
samples.
(B and C) CD34+ peripheral blood mononuclear
cells from three myelofibrosis patients were
transduced with a non-targeting shRNA (scr) or
RECQL5-targeting shRNA (sh1 and sh2) and
cultured on methylcellulose in the presence and
absence of 2 mM HU. After 14 days, total BFU-Es
were counted (B) and genotyped for JAK2V617F
(C). *p < 0.05, **p < 0.01.
(D) Model depicting interactions between
JAK2V617F, RECQL5 depletion, and exogenous
pharmacological replication stress.
See also Figure S4.an increase in DSBs, as indicated by higher numbers of gH2Ax-
positive foci (Figure 3G) and higher levels of gH2Ax by immuno-
blot analysis (Figure 3H). Together, these data demonstrate that
Recql5 is essential to maintain fork stability in mutant JAK2-ex-
pressing cells following exposure to HU.
RECQL5 Depletion Increases the Sensitivity of
JAK2V617F-Positive Cells from MPN Patients to HU
Finally, we tested whether modulation of RECQL5 could also in-
crease the sensitivity of JAK2V617F-positive cells from primary
MPN patients to HU. Following depletion with RECQL5, CD34-
positive peripheral blood mononuclear cells from JAK2V617F-
positivemyelofibrosis patients were grown in semi-solidmedium
supplemented with HU for 14 days (Figure 4A). Strikingly,
following RECQL5 depletion, there was a preferential eradication
of total BFU-E colonies relative to a control shRNA (Figure 4B).
Moreover, genotyping of the colonies for JAK2V617F positivity
revealed a preferential elimination of JAK2V617F-positive
BFU-E colonies compared with autologous wild-type colonies
following exposure to HU (Figure 4C; Figure S4). Collectively,
this indicates that RECQL5 knockdown preferentially sensitizes
JAK2V617F-positive BFU-E colonies fromMPNpatients to phar-
macological induction of replication stress with HU.
DISCUSSION
Chronic MPNs represent amodel of the early stages of leukemo-
genesis and can provide insights into the balance between
oncogene-associated DNA damage and the mechanisms that
act to constrain it. JAK2V617F is the most common molecular
driver of MPNs, and, in PV and ET, it is frequently the sole ge-
netic driver identified. Although there is experimental evidence
demonstrating that JAK2V617F induces DNA damage, clinical
evidence indicates that chronic-phase MPNs follow a relatively
indolent course over decades and that MPN genomes remain
generally stable over time. In this study, we help resolve this
apparent conundrum by demonstrating a role for the DNA
repair helicase RECQL5 in regulating the balance between2350 Cell Reports 13, 2345–2352, December 22, 2015 ª2015 The AuJAK2V617F-induced DNA replication stress and genomic integ-
rity in patients with MPNs.
RECQ helicases are a family of highly conserved genome sur-
veillance enzymes. Humans possess five RECQ helicases—
RECQL1, BLM, WRN, RECQL4, and RECQL5—that have both
unique and overlapping roles in the regulation of DNA replication,
repair, and transcription (Larsen and Hickson, 2013). Strikingly,
we observed that the increased expression of RECQL5 in
JAK2V617F mutant cells was specific and not seen with other
RECQ helicases. This finding precludes the possibility that
increased RECQL5 levels are due to an excess of S phase cells
in cultures of JAK2V617F-expressing cells or that they represent
an epi-phenomenon of increased DNA damage load. Rather, us-
ing shRNA knockdown and various pharmacological agents to
inhibit individual signaling pathways, we demonstrate that
JAK2V617F increases RECQL5 expression through the PI3K-
AKT signaling axis. In terms of the effectors downstream of
PI3K-AKT signaling responsible for mediating RECQL5 activa-
tion, it is possible that a direct transcriptional mechanism, such
asmodulating the activity of the FOXO family of transcription fac-
tors, is involved. Indeed, a similar pathway has been shown pre-
viously to be active in JAK2 mutant cells to modulate expression
of the antioxidant protein catalase (Marty et al., 2013).
The mechanisms by which RECQL5 maintains genomic integ-
rity in normal and cancer cells are ongoing areas of investigation.
Germline loss-of-function mutations in RECQ family members
have been associated with a predisposition to developing can-
cer, and a key role has been described recently for RECQL4 in
hematopoiesis (Smeets et al., 2014). However, RECQL5 dysre-
gulation has not been implicated previously in human disease.
Our data identify increased expression of RECQL5 as a means
by which oncogene-induced replication stress is counteracted
in JAK2-mutated MPNs. Concomitant induction of replication
stress and RECQL5 expression downstream of JAK2-PI3K
signaling potentially forms a feedback loop that regulates DNA
damage accumulation. Depleting RECQL5 in JAK2 mutant cells
disrupts this homeostasis and exposes a synthetic lethal vulner-
ability of JAK2 mutant cells with pharmacological inducers ofthors
replication stress. Following depletion of RECQL5, JAK2V617F-
expressing cells exposed to replication stressors (such as HU or
CPT) exhibit more severe fork stalling and impaired fork restart-
ing in comparison with isogenic wild-type cells. Moreover,
RECQL5-depleted JAK2 mutant cells exhibited higher numbers
of DSBs and underwent apoptosis at lower doses of HU
compared with RECQL5-depleted wild-type cells (Figure 4D).
We envision two mutually non-exclusive scenarios to explain
why JAK2 mutant cells are more sensitive than isogenic wild-
type cells to contemporaneous RECQL5 depletion and exoge-
nous replication stress. First, JAK2V617F-expressing cells are
known to have more replication fork stalling and replication
stress (Chen et al., 2014). Increased RECQL5 expression in
these cells may be required to mitigate replication-associated
genomic instability and maintain an appropriate balance of
DNA damage/repair to ensure cell viability. RECQL5 depletion
in JAK2V617F-expressing cells may therefore be more delete-
rious than to equivalently modified wild-type cells because
JAK2 mutant cells may have less leeway to cope with the
additional replication stress in the form of exogenous administra-
tion of HU. Second, JAK2 mutant cells may exhibit specific
replication fork structures whose resolution is especially depen-
dent on RECQL5 and, therefore, would be particularly sensitive
to RECQL5 depletion. The mechanism of JAK2V617F-induced
replication stress remains unresolved, but is likely to involve
unscheduled euchromatinization during S phase by JAK2
directly (Dawson et al., 2009) or following activation of
downstream STATs (Shi et al., 2006), leading to physical
collisions between the replication machinery and transcriptional
apparatus on the same competing DNA template. The resulting
DNA:RNA hybrid structures (called R loops) are potentially
mutagenic and genome-destabilizing. RECQL5 may play an
important role in resolving R loops in JAK2 mutant cells.
Future studies to distinguish between these possibilities will be
interesting.
Finally, our data may have broader pharmacological implica-
tions for cancer therapy. Although HU remains the frontline treat-
ment for patients with ET and PV (Harrison et al., 2005), most
studies have demonstrated that HUdoes not preferentially target
the V617F-positive cell fraction in ET and PV patients (Antonioli
et al., 2010), and, as a result, HU does not alter the natural history
of MPNs. Our findings highlight a potential approach to amplify
replication stress-associated cytotoxicity through helicase-tar-
geted synthetic lethality. Indeed, there is precedent for this
approach. Inhibition of the Werner helicase using small mole-
cules has been shown to sensitize HeLa and U2OS cells to the
replication stressor topotecan (Aggarwal et al., 2011). Nonethe-
less, the development of small-molecule inhibitors of RECQL5 in
MPNs would need to be approached with caution. In particular,
the safety of RECQL5 inhibition with respect to its potential to
provoke more genomic insults would need to be examined care-
fully. However, exploiting the differential dependencies of cancer
cells on DNA repair pathways has already demonstrated clinical
efficacy through the use of PARP1 inhibitors in BRCA-mutant
cancers (Bryant et al., 2005). Identifying and leveraging synthetic
lethal relationships with DNA helicases may represent another
similar approach for improved anti-cancer treatment strategies
more broadly.Cell RepEXPERIMENTAL PROCEDURES
Generation of Myeloid Progenitor Cell Lines from Jak2V617F
Knockin Mice
Myeloid progenitor cell lines were generated from a C57Bl/6 Jak2V617F-ex-
pressing mouse (Mullally et al., 2010) and from a Jak2 wild-type littermate
control by retroviral overexpression of an estrogen-dependent Hoxb8 tran-
scription factor, as described previously (Wang et al., 2006). Conditionally
immortalized myeloid progenitor cell lines from wild-type mice (WT-B8) and
Jak2V617F knockin mice (VF-B8) were maintained in myeloid medium (RPMI
medium + 10% fetal bovine serum (FBS) supplemented with 50 ng/ml murine
stem cell factor (mSCF) and 1 mM b-estradiol (Sigma).
Cell Viability Assays
WT-B8 and VF-B8 cells were counted, and 5 3 104 cells were seeded in
triplicate in each well of a 96-well plate in 100 ml of myeloid medium. For
drug treatments, agents were added freshly. For serum deprivation studies,
cells were rinsed with 13 PBS twice, and 1 3 105 cells/well were seeded in
a 96-well plate in RPMI medium + 0.5% FBS supplemented with 1 mM b-estra-
diol. Cell growth was measured using a standard Alamar blue assay (Life
Technologies).
Chromosome Combing
Chromosome combing was performed as described previously (Chen et al.,
2014). Briefly, 1 3 105 WT-B8 or VF-B8 cells were seeded in a well of a
96-well plate in a volume of 100 ml. Replicating DNA was first labeled with
25 mM IdU (Sigma), followed by 250 mM CldU) (Sigma) for 20 min each. Cells
were then harvested, genomic DNA was extracted, and individual DNA mole-
cules were stretched on glass slides. The slides were immunostained with flu-
orescently labeled anti-IdU (1:300) and anti-CldU (1:150) and analyzed under
oil immersion on a Zeiss Axioscope 2 fluorescence microscope.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.11.037.
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